Integra Net Debt from 2010 to 2026

IART Stock

USD 9.23 0.06 0.65%

Integra LifeSciences' shows a shrinking structural trend supported by multi-year data. Analyst models indicate potential upside toward approximately 1.9 B. Net Debt is the total debt of Integra LifeSciences Holdings minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1995-09-30

Previous Quarter

1.8 B

Current Value

1.8 B

Quarterly Volatility

571.7 M

Macro event markers

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Financial statement trends for Integra LifeSciences provide structured context on operating performance and capital structure. This context pairs drivers like Depreciation And Amortization of 158.6 M, Interest Expense of 90.6 M or Total Revenue of 1.7 B and ratios such as Price To Sales Ratio of 0.55, Dividend Yield of 3.0E-4 or PTB Ratio of 0.87 with Integra LifeSciences Valuation and Volatility views.

Build AI portfolio with Integra Stock

Integra LifeSciences Correlation provides competitor comparison context for Integra LifeSciences. The view supports competitor context.

The evolution of Net Debt for Integra LifeSciences Holdings provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Integra LifeSciences compares to historical norms and industry peers.

Latest Integra LifeSciences' Net Debt Growth Pattern

Below is the plot of the Net Debt of Integra LifeSciences Holdings over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Integra LifeSciences' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Integra LifeSciences' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Integra Net Debt Regression Statistics

	Arithmetic Mean	1,022,947,400
	Coefficient Of Variation	57.13
	Mean Deviation	500,216,329
	Median	1,173,322,000
	Standard Deviation	584,410,695
	Sample Variance	341535.9T
	Range	1.9B
	R-Value	0.91
	Mean Square Error	61820T
	R-Squared	0.83
	Slope	105,455,052
	Total Sum of Squares	5464573.8T

Integra Net Debt History

	2026	1.9 B
	2025	1.8 B
	2024	1.7 B
	2023	1.4 B
	2022	1.2 B
	2021	1.2 B
	2020	1.2 B

Other Fundumenentals of Integra LifeSciences

Net Debt To E B I T D A

Integra LifeSciences Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Term Debt	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.87	0.92	0.75	0.86	0.96	0.97	0.96	0.98	0.72	0.25	0.9	0.92	-0.13	0.93	0.68	0.9	-0.65	0.9	0.89	0.18	0.22	0.87	0.68	0.44	0.55
Total Stockholder Equity	0.87		0.63	0.86	0.69	0.79	0.74	0.81	0.81	0.49	0.21	0.9	0.66	-0.13	0.76	0.31	0.95	-0.52	0.77	0.86	0.15	0.16	0.85	0.55	0.43	0.16
Net Debt	0.92	0.63		0.54	0.87	0.94	0.98	0.87	0.94	0.72	0.24	0.78	0.96	-0.09	0.89	0.85	0.75	-0.7	0.88	0.76	0.2	0.23	0.74	0.57	0.25	0.66
Retained Earnings	0.75	0.86	0.54		0.57	0.63	0.63	0.73	0.64	0.64	0.25	0.71	0.51	-0.42	0.6	0.37	0.79	-0.23	0.6	0.7	0.01	0.2	0.72	0.7	0.3	0.25
Accounts Payable	0.86	0.69	0.87	0.57		0.93	0.87	0.8	0.86	0.55	0.04	0.75	0.85	-0.11	0.89	0.67	0.75	-0.61	0.79	0.72	0.06	0.02	0.74	0.44	0.32	0.54
Net Receivables	0.96	0.79	0.94	0.63	0.93		0.96	0.91	0.96	0.62	0.2	0.87	0.93	-0.12	0.96	0.71	0.84	-0.68	0.87	0.83	0.18	0.18	0.82	0.53	0.34	0.56
Total Liab	0.97	0.74	0.98	0.63	0.87	0.96		0.94	0.97	0.76	0.25	0.84	0.97	-0.12	0.92	0.8	0.82	-0.67	0.9	0.83	0.19	0.23	0.81	0.66	0.38	0.65
Total Current Assets	0.96	0.81	0.87	0.73	0.8	0.91	0.94		0.9	0.76	0.19	0.82	0.9	-0.26	0.91	0.67	0.79	-0.49	0.83	0.85	0.05	0.16	0.84	0.73	0.56	0.62
Intangible Assets	0.98	0.81	0.94	0.64	0.86	0.96	0.97	0.9		0.66	0.24	0.89	0.94	-0.01	0.91	0.7	0.89	-0.77	0.93	0.86	0.28	0.22	0.82	0.59	0.37	0.53
Short Term Investments	0.72	0.49	0.72	0.64	0.55	0.62	0.76	0.76	0.66		0.22	0.53	0.67	-0.32	0.62	0.67	0.49	-0.15	0.54	0.71	0.06	0.21	0.68	0.8	0.41	0.78
Short Term Debt	0.25	0.21	0.24	0.25	0.04	0.2	0.25	0.19	0.24	0.22		0.39	0.1	0.1	0.21	0.37	0.25	-0.07	0.14	0.19	0.43	1.0	0.13	0.32	-0.35	0.16
Common Stock	0.9	0.9	0.78	0.71	0.75	0.87	0.84	0.82	0.89	0.53	0.39		0.79	0.08	0.83	0.51	0.92	-0.67	0.88	0.87	0.26	0.34	0.86	0.44	0.37	0.24
Long Term Debt	0.92	0.66	0.96	0.51	0.85	0.93	0.97	0.9	0.94	0.67	0.1	0.79		-0.06	0.89	0.79	0.76	-0.74	0.92	0.75	0.18	0.09	0.72	0.52	0.47	0.6
Treasury Stock	-0.13	-0.13	-0.09	-0.42	-0.11	-0.12	-0.12	-0.26	-0.01	-0.32	0.1	0.08	-0.06		-0.21	-0.28	0.01	-0.36	0.08	-0.14	-0.06	0.1	0.0	-0.35	-0.06	-0.26
Property Plant Equipment	0.93	0.76	0.89	0.6	0.89	0.96	0.92	0.91	0.91	0.62	0.21	0.83	0.89	-0.21		0.71	0.77	-0.56	0.78	0.84	0.26	0.19	0.77	0.53	0.4	0.59
Current Deferred Revenue	0.68	0.31	0.85	0.37	0.67	0.71	0.8	0.67	0.7	0.67	0.37	0.51	0.79	-0.28	0.71		0.43	-0.47	0.63	0.48	0.36	0.38	0.37	0.52	0.11	0.71
Good Will	0.9	0.95	0.75	0.79	0.75	0.84	0.82	0.79	0.89	0.49	0.25	0.92	0.76	0.01	0.77	0.43		-0.73	0.88	0.81	0.19	0.2	0.82	0.52	0.31	0.19
Net Tangible Assets	-0.65	-0.52	-0.7	-0.23	-0.61	-0.68	-0.67	-0.49	-0.77	-0.15	-0.07	-0.67	-0.74	-0.36	-0.56	-0.47	-0.73		-0.84	-0.47	-0.31	-0.05	-0.45	-0.11	-0.15	-0.08
Long Term Debt Total	0.9	0.77	0.88	0.6	0.79	0.87	0.9	0.83	0.93	0.54	0.14	0.88	0.92	0.08	0.78	0.63	0.88	-0.84		0.78	0.14	0.1	0.79	0.43	0.39	0.3
Capital Surpluse	0.89	0.86	0.76	0.7	0.72	0.83	0.83	0.85	0.86	0.71	0.19	0.87	0.75	-0.14	0.84	0.48	0.81	-0.47	0.78		0.24	0.14	0.93	0.54	0.47	0.41
Deferred Long Term Liab	0.18	0.15	0.2	0.01	0.06	0.18	0.19	0.05	0.28	0.06	0.43	0.26	0.18	-0.06	0.26	0.36	0.19	-0.31	0.14	0.24		0.43	-0.05	-0.01	-0.09	0.04
Short Long Term Debt	0.22	0.16	0.23	0.2	0.02	0.18	0.23	0.16	0.22	0.21	1.0	0.34	0.09	0.1	0.19	0.38	0.2	-0.05	0.1	0.14	0.43		0.08	0.31	-0.38	0.19
Long Term Investments	0.87	0.85	0.74	0.72	0.74	0.82	0.81	0.84	0.82	0.68	0.13	0.86	0.72	0.0	0.77	0.37	0.82	-0.45	0.79	0.93	-0.05	0.08		0.53	0.47	0.38
Net Invested Capital	0.68	0.55	0.57	0.7	0.44	0.53	0.66	0.73	0.59	0.8	0.32	0.44	0.52	-0.35	0.53	0.52	0.52	-0.11	0.43	0.54	-0.01	0.31	0.53		0.34	0.71
Net Working Capital	0.44	0.43	0.25	0.3	0.32	0.34	0.38	0.56	0.37	0.41	-0.35	0.37	0.47	-0.06	0.4	0.11	0.31	-0.15	0.39	0.47	-0.09	-0.38	0.47	0.34		0.3
Capital Stock	0.55	0.16	0.66	0.25	0.54	0.56	0.65	0.62	0.53	0.78	0.16	0.24	0.6	-0.26	0.59	0.71	0.19	-0.08	0.3	0.41	0.04	0.19	0.38	0.71	0.3

Click cells to compare fundamentals

Stock Overview, Methodology & Data Sources

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. Integra Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 3800 people. As a small-cap equity, Integra LifeSciences is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 26.94, P/B of 0.72, profit margin of -31.58%. Integra LifeSciences has a market cap of 748.98 M, P/E of 26.94, ROE of -39.9%.

Methodology

Unless otherwise specified, financial data for Integra LifeSciences Holdings is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Integra (USA Stocks:IART) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Integra LifeSciences Holdings is covered by 11 analysts. 5 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, Raymond James, Bernstein Research, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Integra Stock Analysis

	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Integra Net Debt from 2010 to 2026

Latest Integra LifeSciences' Net Debt Growth Pattern

Integra Net Debt Regression Statistics

Integra Net Debt History

Other Fundumenentals of Integra LifeSciences

Integra LifeSciences Net Debt component correlations

Stock Overview, Methodology & Data Sources

Methodology

Analyst Sources

This content is curated and reviewed by:

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Integra Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY